Inogen (NSDQ:INGN) this week announced that it has appointed Stanislav Glezer as chief technology officer.
Glezer will be responsible for R&D and engineering, medical affairs and regulatory affairs. He joined the company in June this year as chief medical officer and will remain an EVP at the company.
Prior to joining the company, Glezer held numerous leadership roles at medical technology and biotechnology firms like BD, Adocia, Novo Nordisk and Sanofi.
Goleta, California-based Inogen also said that Executive VP of Engineering Brenton Taylor will leave the company following a transition period ending April 1, 2022.
“Since joining Inogen as chief medical officer earlier this year, Stan has made a significant impact in helping us instill clinically-informed discipline in innovation, product development practices and go-to-market strategy. In this new role, Stan’s deep background in clinical research, success in developing, commercializing, and securing access for new innovations will be vital as we drive the next phase of growth and shareholder value creation,” President and CEO Nabil Shabshab said in a news release. “On behalf of all of us at Inogen, I want to thank Brenton for the instrumental role he played in founding Inogen and being an important part of its growth journey so far. We look forward to working with him on a seamless transition of his duties over the next several months and wish him well in his future endeavors.”
“Since joining Inogen, my view of the tremendous opportunity that lies ahead to develop products that meaningfully improve patient outcomes has only deepened,” Glezer said. “In this expanded role, I look forward to continuing our efforts to develop an integrated innovation strategy and agenda as well as to expand our collaboration with health care practitioners and technology experts to develop clinical solutions that support patients, enhance our market position and drive value for shareholders.”
